Skip to content
Clinical Trials – home

Azienda Provinciale Per I Servizi Sanitari

Verified siteinfo

Italy Largo Medaglie D' Oro 9, 38122 Trento, Italy

  • 21 trials recruiting
  • Prostate cancer metastatic · Breast cancer · Hormone-refractory prostate cancer
  • Adults and children

About Specializations

Azienda Provinciale Per I Servizi Sanitari in Trento, Italy specialises in clinical trials of conditions such as Prostate cancer metastatic, Breast cancer, Hormone-refractory prostate cancer, Prostate cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Breast Cancer Research

At Azienda Provinciale Per I Servizi Sanitari, clinical trials in oncology focus strongly on breast cancer, including early-stage, hormone receptor-positive, triple-negative, HER2-positive, and metastatic disease. These studies are designed to test new treatment approaches, compare active therapies, and improve outcomes after surgery or standard treatment.

  • Testing new combinations for triple-negative breast cancer and high-risk disease after surgery
  • Evaluating targeted and endocrine-based strategies in hormone receptor-positive, HER2-negative breast cancer
  • Studying treatment options for metastatic breast cancer and HER2-positive breast cancer

Research in this area aims to extend disease control, reduce recurrence, and better tailor treatment to the biology of each tumor.

Prostate Cancer and Genitourinary Oncology

The site has a major research focus on prostate cancer, especially metastatic castration-resistant and metastatic castration-sensitive prostate cancer. Trials are exploring new hormonal, targeted, and combination therapies to improve survival, delay progression, and support men with advanced disease.

  • Investigating treatment effectiveness in mCRPC and mCSPC
  • Studying therapies for patients with HRR or BRCA-related tumor features
  • Assessing symptom control and quality of life in advanced prostate cancer

These studies reflect a broad effort to refine care for advanced genitourinary cancers and identify more personalized treatment pathways.

Melanoma and Immunotherapy

Clinical research at the U.O. di Oncologia Medica Ospedale S. Chiara -Trento also includes melanoma, with trials centered on immunotherapy and newer treatment combinations. The goal is to improve disease control in advanced and metastatic cases while comparing promising options against current standard care.

  • Evaluating immune-based treatment strategies for advanced melanoma
  • Comparing new combinations with established checkpoint inhibitor approaches
  • Measuring progression control and overall benefit in metastatic skin cancer

This area highlights the site’s role in advancing treatments that harness the immune system against aggressive cancers.

Colorectal Cancer and ctDNA-Guided Care

Another important field is colorectal cancer, where trials are examining how to improve treatment after surgery and in advanced disease. Several studies focus on ctDNA-guided strategies, aiming to better identify patients who may benefit from treatment intensification or closer follow-up.

  • Testing treatment strategies for stage III and high-risk resected colon cancer
  • Exploring sequencing approaches in metastatic colorectal cancer
  • Using ctDNA to support more precise post-operative decision-making

These studies are designed to improve recurrence prevention and make treatment planning more individualized for patients with gastrointestinal cancers.

Endometrial Cancer and Gynecologic Oncology

Trials in gynecologic oncology include research on endometrial cancer, particularly recurrent or advanced disease. The studies are aimed at evaluating whether new treatment combinations can improve survival and delay disease progression.

  • Studying treatment options for advanced endometrial cancer
  • Assessing benefit in different tumor subgroups, including MMR and MSI profiles
  • Comparing combination approaches with standard therapy

This work supports better treatment selection for women with difficult-to-treat female reproductive system cancers.

Respiratory, Renal, and Immune-Mediated Diseases

Beyond cancer, the site participates in studies on immune system diseases, kidney cancer, and lung cancer. These trials are focused on testing new therapies, improving disease control, and evaluating whether surgery or other treatment strategies add benefit alongside modern systemic care.

  • Investigating treatment for eosinophilic granulomatosis with polyangiitis
  • Studying approaches for metastatic renal cell carcinoma and metastatic NSCLC
  • Evaluating whether treatment strategies can improve survival and disease management

This broad portfolio shows active research across both oncology and selected inflammatory diseases, with an emphasis on better outcomes and more effective care.

Diagnostic, Supportive, and Procedural Research

The site also contributes to trials in diagnostic techniques, supportive care, and procedure-related research. These studies aim to improve how patients are prepared, monitored, and treated in routine clinical settings, including research relevant to colonoscopy and pain management.

  • Improving bowel preparation for colonoscopy
  • Testing a new approach for chronic pelvic pain syndrome
  • Supporting better diagnostic and treatment-related clinical practice

Such studies complement the oncology program by addressing patient comfort, diagnostic quality, and everyday care needs at the hospital level.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Largo Medaglie D' Oro 938122 TrentoItaly
Recruiting now
21 trials
Conditions studied
39
Partner status
Verified site

More sites in TrentoItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

52 clinical trials

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Study of Piperacillin and Tazobactam Given Under the Skin Compared to a Vein in Patients with Infectious Diseases

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Piperacillin
  • Sponsor:Azienda Sanitaria Universitaria Friuli Centrale

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Prostate cancer

Recruiting

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

Prostate cancer

Recruiting

A study testing ASP5541 compared to abiraterone acetate in patients with advanced prostate cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astellas Pharma Global Development Inc.

Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Study on the Effects of Tumor Removal in Patients with Metastatic Kidney Cancer Treated with Nivolumab and Ipilimumab Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study Comparing Docetaxel and Androgen Receptor-Targeted Agents (Abiraterone or Enzalutamide) for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Pneumonia

Recruiting

Study on the Effects of Oseltamivir and Drug Combination for Patients with Pneumonia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baloxavir Marboxil
  • Sponsor:University Of Oxford
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.